कंपनी का अवलोकन
KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical entity dedicated to developing oral therapies designed to address rare diseases characterized by unmet medical needs. The company functions within the healthcare sector, specifically the biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles aimed at creating novel medical treatments. According to available data, the firm employs 275 individuals and holds a market capitalization of $1.02B with an annual revenue of $73.62M over the trailing twelve months. These valuation and revenue figures indicate that KalVista occupies a mid-cap position within the biotechnology landscape, suggesting it has moved beyond the initial seed stage but is still scaling its commercial operations relative to the substantial $1.02B market value it commands.
वित्तीय स्वास्थ्य
The company reported a revenue of $73.62M for the trailing twelve months, yet it recorded a net income of -$164,286,000 and an EBITDA of -$164,816,992. The significant gap between the positive revenue of $73.62M and the substantial net loss of -$164,286,000 reveals a cost structure where operating expenses, likely driven by research and development or administrative costs, far exceed current sales proceeds. The company currently has no reported free cash flow, indicating that cash generation from operations is being consumed by capital expenditures or working capital requirements, which limits immediate financial flexibility for large-scale acquisitions. Analysis of the three key margins shows a gross margin of 25.7%, reflecting moderate efficiency in production costs relative to sales, while the operating margin stands at -21.2% and the profit margin is significantly negative at -223.2%. The extremely negative profit margin of -223.2% underscores that the company is losing more than two dollars for every dollar of revenue due to high fixed costs or pre-commercial stage losses. On the balance sheet, KalVista holds $300.21M in cash against $284.21M in debt, resulting in a debt-to-equity ratio that is not explicitly quantified in standard terms but indicates a leveraged position where cash reserves nearly cover total liabilities. The current ratio is 5.58, which indicates a highly liquid balance sheet with current assets significantly exceeding current liabilities, ensuring strong short-term liquidity despite the operating losses. Furthermore, the Return on Equity (ROE) and Return on Assets (ROA) are not available due to the net loss position, which reveals that management effectiveness in generating returns is currently being measured by capital preservation rather than profit generation.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not available due to negative earnings, whereas the forward P/E is 19.84. The absence of a trailing P/E compared to the existence of a forward P/E of 19.84 implies that the market expects earnings to turn positive in the future, creating a divergence between historical profitability and projected earnings trajectory. The price-to-book ratio is reported as -376.42, which indicates a severe market premium or discount relative to book value, often seen in biotech firms where intangible assets like intellectual property outweigh recorded book assets. Additionally, the price-to-sales ratio is 13.88 and the EV/EBITDA is -6.10. These alternative valuation metrics suggest that the market is pricing the company primarily on its revenue potential and pipeline value rather than current cash flows or earnings power. The stock has traded between a 52-week high of $21.30 and a 52-week low of $9.23. Without a specific current price listed in the facts, the valuation context relies on these historical bounds to define the trading range within which the stock has fluctuated over the past year. The beta value is -0.40, which is an unusual negative figure indicating that the stock's price volatility moves inversely to the broader market, offering a distinct risk profile compared to the standard positive correlation of most equities.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are not available in the current data set. The unavailability of these growth rates prevents a direct comparison of whether earnings are growing faster or slower than revenue, but the negative earnings trajectory suggests the company is not yet profitable. For non-dividend payers, KalVista has a dividend yield of N/A and a payout ratio of 0.0%. This 0.0% payout ratio indicates that the company does not distribute any earnings to shareholders, which is typical for biotechnology firms reinvesting all available capital into research and development to advance their pipeline. Consequently, the company reinvests earnings into growth rather than paying dividends, a strategy aligned with its biopharmaceutical development lifecycle. The overall growth and income profile is characterized by a focus on capital appreciation through product development rather than income generation via dividends or current profitability, as evidenced by the lack of dividend history and the absence of positive year-over-year growth metrics.